MERUS
Merus B.V., a biomedical company, engages in the discovery and development of antibody-based biopharmaceuticals. It develops Oligoclonics technology that offers a class of human antibodies, called Oligoclonics. Oligoclonics is a concept whereby a mixture of various human therapeutic antibodies, directed to a common antigen are produced from a single cell clone. The company was founded in 2003 and is based in Driebergen, the Netherlands.
MERUS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2003-01-01
Address:
Utrecht, Utrecht, The Netherlands
Country:
The Netherlands
Website Url:
http://www.merus.nl
Total Employee:
101+
Status:
Active
Contact:
31 30 253 8800
Email Addresses:
[email protected]
Total Funding:
288.84 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Actigen Ltd
Actigen Ltd is an biotechnology company engaged in the development of human antibody therapeutics.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Allinky Biopharma
Allinky Biopharma is a company dedicated to the discovery and development of novel therapeutic agents
MorphoSys
MorphoSys is a biotechnology company focused on the research and development of fully human antibodies.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Sofinnova Investments
Sofinnova Investments investment in Post-IPO Equity - Merus
Life Sciences Partners
Life Sciences Partners investment in Post-IPO Equity - Merus
Biotechnology Value Fund
Biotechnology Value Fund investment in Post-IPO Equity - Merus
RA Capital Management
RA Capital Management investment in Series C - Merus
Bay City Capital
Bay City Capital investment in Series C - Merus
Novo Holdings
Novo Holdings investment in Series C - Merus
Tekla Capital Management
Tekla Capital Management investment in Series C - Merus
Johnson & Johnson Innovation
Johnson & Johnson Innovation investment in Series C - Merus
Life Sciences Partners
Life Sciences Partners investment in Series C - Merus
Rock Springs Capital
Rock Springs Capital investment in Series C - Merus
Key Employee Changes
| Date | New article |
|---|---|
| 2020-07-27 | Merus Appoints Andrew Joe, M.D., as Chief Medical Officer |
| 2019-12-16 | Merus Announces Chief Executive Officer Transition |
Official Site Inspections
http://www.merus.nl Semrush global rank: 2.95 M Semrush visits lastest month: 5.51 K
- Host name: 7.207.243.35.bc.googleusercontent.com
- IP address: 35.243.207.7
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
